NeurologyLive®
LightNews LightNews
banner
neurologylive.bsky.social
NeurologyLive®
@neurologylive.bsky.social
290 followers 61 following 65 posts
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments

Read our coverage: neurologylive.com
Posts Replies Media Videos
neurologylive.bsky.social
🚨 New Podcast Ep.!

NEALS 2025: Takeaways That Matter for ALS Care - Featuring Dr. Berry and Dr. Andrews!

Listen as they reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for #ALS.

👂 ➡️ www.neurologylive.com/view/episode...
#MindMoments #Podcast
Episode 154: NEALS 2025: Takeaways That Matter for ALS Care | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Berry, MD, MPH; and Jinsy Andrews, MD, MSc. [LISTEN TIME: 28 minutes]
www.neurologylive.com
November 14, 2025 at 2:08 PM
neurologylive.bsky.social
Breakthrough for #Parkinson patients:

iPSC therapy UX-DA001 boosts motor function & dopamine activity—without serious side effects. Learn how #CellTherapy may transform brain repair. 🧠

Read the full story 👉 www.neurologylive.com/view/therape... #StemCellTherapy #NeuroResearch #Neurology #Health
Therapeutic Potential and Early Promise Behind Stem Cell Therapy UX-DA001 in Parkinson Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Liche Zhou, MD, of the department of neurology at Jiang University School of Medicine, provided commentary on new phase 1 data on an iPSC-targeted cell therapy presented at the 2025 MDS Congress.
www.neurologylive.com
November 13, 2025 at 2:07 PM
neurologylive.bsky.social
🌍 A new dawn for #RareDisease care: #FDA approves Kygevvi, the first treatment for thymidine kinase 2 deficiency (TK2d).

💡 Data show an 86% reduction in mortality risk — a life-changing advance for patients & families.

Read here: www.neurologylive.com/view/neurovo...

#Neurology #Innovation
NeuroVoices: Fabian Somers, PhD, on the First Approved Drug for Thymidine Kinase 2 Deficiency | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The vice president and Asset Head of Rare and Ultra-Rare Diseases at UCB provided clinical perspectives on the FDA approval of Kygevvi, the first marketed treatment specific for patients with thymidin...
www.neurologylive.com
November 12, 2025 at 3:58 PM
neurologylive.bsky.social
Caregivers are open to talking about social determinants of health (SDoH) — but prefer surveys over face-to-face discussions.

A new study finds many want to focus clinic time on their child’s care while still sharing key life factors that affect health.

🔗 ➡️ www.neurologylive.com/view/study-s...
Study Shows Caregivers Willing to Discuss Social Determinants of Health in Pediatric Multidisciplinary Clinics | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Caregivers share insights on discussing social determinants of health in pediatric clinics, revealing preferences for surveys over in-person conversations.
www.neurologylive.com
November 11, 2025 at 2:08 PM
neurologylive.bsky.social
🧠 This Week on #NeurologyLive
From conference coverage to video interviews to up to the minute news — we’re diving into the latest research, expert insights, and clinical updates shaping the field of #neurology.

Don’t miss this week’s coverage 👉 www.neurologylive.com
#BrainHealth #NeurologyUpdates
November 10, 2025 at 2:25 PM
neurologylive.bsky.social
⚡ EVs may reduce emissions — but could they raise neurologic risks globally?

Dr. Brad Racette (Barrow Neurological Institute) explores how EV production shifts environmental & neurotoxic burdens to the global south.

Read more 👉 www.neurologylive.com/view/overvie...
#EVs #Risks #Neurology #Health
Overviewing the Neurologic Risks Behind Electric Vehicles | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Brad Racette, MD, FAAN, the Kemper and Ethel Marley Chair for Neurology at Barrow Neurological Institute, discussed his keynote lecture on the neurologic health effects of electric vehicles and the gl...
www.neurologylive.com
November 7, 2025 at 3:27 PM
neurologylive.bsky.social
💡 Promising results for #ALS patients!

Phase 2a data show SPG302 (Spinogenix’s synaptic regenerative drug) slowed ALS progression by 76% vs historical controls, with 82% of patients showing stable or improved function.

Read more: www.neurologylive.com/view/prelimi...
#Neuroscience #Neurology
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Spinogenics presents promising data on SPG302, a daily tablet showing cognitive improvements in Alzheimer's patients with excellent safety profiles.
www.neurologylive.com
November 6, 2025 at 2:06 PM
neurologylive.bsky.social
In case you missed it:

🚨 Breaking: FDA Approves First Treatment for TK2 Deficiency

The #FDA has approved Kygevvi — a fixed-dose combo of doxecitine + doxribtine — as the first-ever therapy for thymidine kinase 2 deficiency.

Stay up to date here: www.neurologylive.com/view/fda-app...
#Neurology
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
UCB's Kygevvi becomes the first FDA-approved treatment for thymidine kinase 2 deficiency, offering hope to patients with this rare neuromuscular disorder.
www.neurologylive.com
November 5, 2025 at 4:15 PM
neurologylive.bsky.social
A new #Phase3 trial, RELIEVE, is underway to evaluate remibrutinib, a potent oral BTK inhibitor, in #gMG.

💊 Builds on strong safety data from autoimmune studies and FDA approval in CSU.
🧬 Could mark a new era in targeted gMG treatment.

Read here: www.neurologylive.com/view/new-pha...
#Neurology
New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
A phase 3 study evaluates remibrutinib's safety and efficacy for generalized myasthenia gravis, promising new treatment options for patients.
www.neurologylive.com
November 4, 2025 at 2:01 PM
neurologylive.bsky.social
🧠 This Week on NeurologyLive® — Nov 3, 2025

From #Alzheimer’s and #epilepsy to sleep and stroke, we’re diving into the week’s hottest topics in neurology. Explore expert insights, in-depth analyses, and clinical updates designed for professionals in the field.

🔗 neurologylive.com

#Neurology #Care
NeurologyLive - Clinical Neurology News and Neurology Expert Insights
NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.
neurologylive.com
November 3, 2025 at 2:05 PM
Reposted by NeurologyLive®
ijmsc.bsky.social
The results from our #AI in #MultipleSclerosis survey are in. Take a look over on @neurologylive.bsky.social.

www.neurologylive.com/view/ai-in-m...
AI in MS: IJMSC Survey Results | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
A video that shares the sentiments and opinions of the IJMSC community on the use of artificial intelligence in multiple sclerosis care, research, and publication.
www.neurologylive.com
November 3, 2025 at 1:16 PM
neurologylive.bsky.social
🎃 This Halloween, neurology meets history 📜

Avi Singh Gandh, MD, explores how the “bewitchments” of the 1692 Salem Witch Trials may reflect epilepsy, FND, and more —reminding us how science turns fear into understanding.

Read more: www.neurologylive.com/view/revisit...

#Halloween #AAN25 #Spooky
Revisiting the Salem Witch Trials Through a Modern Neurological Lens | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Avi Singh Gandh, MD, neurology resident at Emory University School of Medicine, reflected on how modern neurology can interpret the Salem Witch Trials.
www.neurologylive.com
October 31, 2025 at 1:08 PM
neurologylive.bsky.social
This #WorldStrokeDay, Cleveland Clinic’s Dr. Andrew Russman highlights how most strokes stem from identifiable and modifiable risks — and how precision medicine and heart–brain collaboration are reshaping prevention.

Read more via NeurologyLive®: www.neurologylive.com/view/honorin...
Honoring World Stroke Day: Insights on Systemic Stroke Risk and Prevention Strategies | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Andrew Russman, DO, medical director of Cleveland Clinic’s Comprehensive Stroke Center, shared insights on stroke awareness, prevention, and the growing importance of heart-brain collaboration in care...
www.neurologylive.com
October 30, 2025 at 1:04 PM
neurologylive.bsky.social
❤️ “Maintaining healthy numbers for Life’s Essential 8 can reduce the risk of #stroke and #dementia.”
— Dr. Mitch Elkind

Ahead of #WorldStrokeDay, NeurologyLive® spoke with Dr. Elkind on prevention, equity, and the future of brain health.

Read more: www.neurologylive.com/view/neurovo...

#Health
NeuroVoices: Mitch Elkind, MD, MS, FAHA, on Enhancing Brain Health Amid World Stroke Day | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The chief science officer at the American Heart Association discusses the AHA’s priorities for stroke prevention, cross-specialty collaboration, and equitable care as clinicians mark World Stroke Day ...
www.neurologylive.com
October 29, 2025 at 1:19 PM
neurologylive.bsky.social
🚨 FDA Accepts NDA for MK-6240 — a PET imaging agent targeting tau protein in #Alzheimer disease.

🔬 Developed by Lantheus, MK-6240 aims to improve early diagnosis and guide treatment strategies for patients with cognitive impairment.

📖 Read more: www.neurologylive.com/view/fda-acc...
#FDA #News
FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The FDA accepts Lantheus' MK-6240 application, a promising PET imaging agent for Alzheimer disease, enhancing diagnosis and treatment strategies.
www.neurologylive.com
October 28, 2025 at 5:45 PM
neurologylive.bsky.social
This Week’s Preview 🫣

Stay ahead in neurology with our latest coverage! Coming up: exclusive clinician interviews, continued conference insights, a new podcast episode, and more.

🕐 Take 5 minutes to stay informed → www.neurologylive.com/view/this-we...
#Neurology #Research
This Week on NeurologyLive® — October 27, 2025 | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Here's some of what is coming soon to NeurologyLive® this week.
www.neurologylive.com
October 27, 2025 at 1:25 PM
neurologylive.bsky.social
"Lifestyle factors are not secondary—they’re central"

New insights from Dr. James N. Brenton at the 2025 Child Neurology Society Annual Meeting on how #diet, vitamin D, and obesity impact pediatric MS progression—and why coordinated care matters.

Full article: www.neurologylive.com/view/integra...
Integrating Nutrition and Lifestyle Strategies in Pediatric Multiple Sclerosis Management | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
James N. Brenton, MD, director of the Pediatric MS and Related Disorders Clinic at the University of Virginia, discussed how lifestyle modification and multidisciplinary care can support disease manag...
www.neurologylive.com
October 24, 2025 at 1:13 PM
neurologylive.bsky.social
🧠 The NeurologyLive® team was on-site at #MDS2025 in Honolulu, bringing you exclusive interviews and updates from the floor!
Hear from experts like Jonas Hannestad, MD, PhD, on the latest in Parkinson’s disease research and novel therapies:
Check out the 🔗 here: www.neurologylive.com/view/mds-con...
MDS Congress 2025: Top Expert Interviews and Key Takeaways | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 2025 International Congress of Parkinson’s Disease and Movement Disorders (MD...
www.neurologylive.com
October 23, 2025 at 2:07 PM
Reposted by NeurologyLive®
mda.org
🚨 Registration is OPEN! 🚨
Join us March 8–11, 2026 in Orlando for the #MDAConference, the leading global event for neuromuscular care & research. 🌍🧬

🔗 Register now: www.mdaconference.org

#MDA #MuscularDystrophy #neuromuscular
August 21, 2025 at 5:46 PM
neurologylive.bsky.social
🚨 Just launched: our expert interview collection from AAIC 2025!
From novel blood-based biomarkers to tau-targeting therapies and scalable digital tools, top researchers and clinicians shared insights into where Alzheimer care is headed.
🧠 Take a look→
www.neurologylive.com/view/aaic-20...
AAIC 2025: Top Interviews and Key Takeaways
Discover groundbreaking insights from the 2025 Alzheimer’s Association International Conference, featuring expert interviews on innovative treatments and diagnostics.
www.neurologylive.com
August 13, 2025 at 6:08 PM
neurologylive.bsky.social
🧠🤔 In our Q&A, MIT’s Daniel Freedman, PhD, explains how Openwater’s Open-LIFU is enabling precise deep-brain access for studying how the conscious experience arises from brain activity, exploring treatments for pain, depression, and more.

Read now: www.neurologylive.com/view/openwat...
Openwater’s LIFU Technology at MIT: A New Era for Consciousness and Neurological Care
Daniel Freedman, PhD, of MIT, gave clinical commentary on how how Openwater’s Open-LIFU enables new research into conscious perception and potential clinical applications for conditions like pain and ...
www.neurologylive.com
August 8, 2025 at 1:42 PM
neurologylive.bsky.social
🚨FDA has approved fremanezumab (Ajovy) as the first anti-CGRP preventive treatment for pediatric episodic migraine, expanding care options for children and adolescents aged 6 to 17. Approval was supported by phase 3 SPACE study results.

📰Read more now: www.neurologylive.com/view/fda-app...
FDA Approves Fremanezumab as First Anti-CGRP Preventive Therapy for Pediatric Episodic Migraine
Teva's fremanezumab gains FDA approval for pediatric migraine prevention, offering a vital treatment option for children aged 6-17.
www.neurologylive.com
August 6, 2025 at 1:30 PM
neurologylive.bsky.social
🧠 #AAIC25: ABvac40, a developing Alzheimer vaccine from Grifols, showed a significant reduction in cognitive decline in a phase 2 trial, and all met primary endpoints with no significant safety concerns 👏

Read more now: www.neurologylive.com/view/alzheim...
Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study
NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.
www.neurologylive.com
August 4, 2025 at 5:49 PM
neurologylive.bsky.social
🧠 At #AAIC25, Sharron Gargosky, PhD, shared promising early data from Spinogenix’s phase 2 trial of SPG302 in #AD. The synaptogenic small molecule showed early signs of cognitive improvement and was well tolerated over 28 weeks 👏

Read more now: www.neurologylive.com/view/finding...
Findings From First Cohort of SPG302 in Phase 2 Alzheimer Disease Trial: Sharron Gargosky, PhD
The chief development officer at Spinogenix shared initial results from the first cohort of the company’s phase 2 trial assessing SPG302 in Alzheimer disease presented at AAIC 2025. [WATCH TIME: 6 min...
www.neurologylive.com
August 1, 2025 at 6:47 PM
neurologylive.bsky.social
🧠 As patients grow up, care must grow with them, and support makes all the difference.

In this new feature, Susan Duberstein, MD, PhD, outlines how continuity of care, patient education, and psychosocial support can smooth this critical journey ❤️

Learn more: www.neurologylive.com/view/the-tra...
The Transition of Care from Pediatric to Adult Neurology: Leaving the Cocoon
Navigating the transition from pediatric to adult neurology involves careful planning, education, and support to ensure optimal care and independence for young adults.
www.neurologylive.com
July 31, 2025 at 1:53 PM